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Integrating Pathway Analysis and Genetics
of Gene Expression for Genome-wide Association Studies
Hua Zhong,1,3,* Xia Yang,1 Lee M. Kaplan,2 Cliona Molony,1,4 and Eric E. Schadt1,5
Genome-wide association studies (GWAS) have achieved great success identifying common genetic variants associated with common
human diseases. However, to date, the massive amounts of data generated from GWAS have not been maximally leveraged and inte-
grated with other types of data to identify associations beyond those associations that meet the stringent genome-wide signiﬁcance
threshold. Here, we present a novel approach that leverages information from genetics of gene expression studies to identify biological
pathways enriched for expression-associated genetic loci associated with disease in publicly available GWAS results. Speciﬁcally, we ﬁrst
identify SNPs in population-based human cohorts that associate with the expression of genes (eSNPs) in the metabolically active tissues
liver, subcutaneous adipose, and omental adipose. We then use this functionally annotated set of SNPs to investigate pathways enriched
for eSNPs associated with disease in publicly available GWAS data. As an example, we tested 110 pathways from the Kyoto Encylopedia
of Genes and Genomes (KEGG) database and identiﬁed 16 pathways enriched for genes corresponding to eSNPs that show evidence of
association with type 2 diabetes (T2D) in the Wellcome Trust Case Control Consortium (WTCCC) T2D GWAS. We then replicated these
ﬁndings in the Diabetes Genetics Replication andMeta-analysis (DIAGRAM) study. Many of the pathways identiﬁed have been proposed
as important candidate pathways for T2D, including the calcium signaling pathway, the PPAR signaling pathway, and TGF-b signaling.
Importantly, we identiﬁed other pathways not previously associated with T2D, including the tight junction, complement and coagula-
tion pathway, and antigen processing and presentation pathway. The integration of pathways and eSNPs provides putative functional
bridges between GWAS and candidate genes or pathways, thus serving as a potential powerful approach to identifying biological mech-
anisms underlying GWAS ﬁndings.Genome-wide association studies (GWAS) have revolution-
ized our ability to localize and identify the causal determi-
nants for common human diseases over the past several
years, delivering an unprecedented number of DNA loci
associated with a diversity of common human diseases
such as type 1 diabetes (T1D),1 coronary artery disease,2
HIV-1 infection,3 and type 2 diabetes (T2D).3–8 However,
GWAS do not necessarily lead directly to the gene or
genes in a given locus associated with disease, and they
do not typically inform the broader context in which the
disease genes operate, thereby providing limited insights
into the mechanisms driving disease.9–11 Furthermore,
the amount of genetic variation explained by GWAS for a
given disease is most often signiﬁcantly less than the heri-
tability estimated for the disease. For example, a number of
studies estimate the genetic heritability for T2D to be as
high as 40%,12 but the 18 DNA loci identiﬁed for T2D
to date account for only ~3% of the variation in T2D.7
This raises the question of whether there are many more
common DNA variants with smaller effects that are not
being identiﬁed in the GWAS because of a lack of power,
whether there are many more rare variants with stronger
effects that explain the missing variation, or whether it is
some combination of these two explanations.13,14
Biological pathway-based analysis is a complementary
approach to single-point analyses. Generally, this type of
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Gene Set Enrichment Analysis (GSEA) represents one of
the ﬁrst approaches of this type developed to identify
gene sets, rather than individual genes, from gene expres-
sion data that are associated with phenotypes of interest.15
AmodiﬁedversionofGSEAwas recently developed for anal-
ysisofGWASdata, inwhichSNPsetsderived frombiological
gene sets are collectively tested for association to disease.16
This modiﬁed GSEA method has been applied to T2D
GWAS17 and has been evaluated to assess whether it
could help prioritize biological pathways associated with
T2D.18 Variations of this approach using a hypergeometric
model have been developed to determine pathways
that were enriched for seven common diseases with the
use of GWAS results,19 and other more ﬂexible methods to
combine association evidence of SNPs or genes within a
pathway have also been developed.20 A common theme in
all of these developments has been to analyze GWAS data
by testing for association of a pathway rather than testing
individual genes in order to identify multiple variants asso-
ciated with disease in multiple related genes, in which the
variants individually do not necessarily meet the GWAS
genome-wide signiﬁcance threshold.16 In some cases, these
approaches have provided important biological insights
into the mechanisms underlying disease pathogenesis.
There is one open yet very important question when
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data. A typical genemay span tens to hundreds of common
SNPs, yet only one or a few of them may be functional or
linked closely enough to the underlying causative variant
to serve as a useful surrogate.16 Several approaches have
been devised to represent any given gene by one or more
SNPs from GWAS data. The maximum statistic for all SNPs
near a gene has been used to represent the signiﬁcance of
the gene,16,19 and linkage disequilibrium (LD) information
has also been used to map the signiﬁcant SNPs to adjacent
genes.18However,most SNPs in a gene regionwill not repre-
sent functional variants of the gene, and a true disease-
associated genemayhavemultiple independent functional
variants. Furthermore, a gene may be regulated in trans by
DNA variants that are far away from the structural gene.11
In this paper, we propose and demonstrate that by inte-
grating information from genetics of gene expression
(GGE) studies and pathway-based analyses in GWAS
provides for additional power to uncover important biolog-
ical pathways and insights into disease etiology.
GGE studies have provided away to address several of the
limitations of conventional GWAS analysis.10,11,21–23 By
mapping the genetic architecture of gene expression in
human populations, GGE studies can provide functional
support for candidate genes within a given locus.11,21,24
One way that GGE studies can affect interpretation of
GWAS is to provide links between signiﬁcant GWAS SNPs
and genes whose expression levels have been associated
with those DNA variants.11 Recently, detailed GGE studies
have proﬁled transcripts and genotyped SNPs across the
human genome in moderate to large population-based
human cohorts.11,23,25,26 These GGE studies resulted in
the detection of SNPs associated with gene expression
(termed expression SNPs or eSNPs) in disease-relevant
tissues. The eSNPs can be considered as functionally rele-
vant SNP sets for genetic analysis and provide a biological
justiﬁcation for using the p values of the corresponding
eSNPs to represent the signiﬁcance levels of a gene with
respect to disease association.
On the basis of eSNPs discovered from liver and adipose
tissues of two independent human cohorts,11 we derived
eSNP sets that represent genes in pathways deﬁned by
the Kyoto Encylopedia of Genes and Genomes (KEGG)
pathway database.27 We then extracted the GWAS associa-
tion p values of these pathway-dependent eSNPs to T2D
traits from the Wellcome Trust Case Control Consortium
(WTCCC) cohort28 and analyzed the enrichment of low-
association p values among these pathway eSNPs.We repli-
cated a large proportion of the identiﬁed top pathways by
using GWAS results from the Diabetes Genetics Replication
and Meta-analysis (DIAGRAM) Consortium. This integra-
tive genomics approach allows us to address whether
GGE studies can help uncover important biological genes
and pathways that underlie the complex etiology of T2D
that may otherwise be missed by merely focusing on indi-
vidual signiﬁcant GWAS SNPs.
The ﬁrst GGE study proﬁled more than 39,000 tran-
scripts and genotyped 782,476 unique SNPs in more582 The American Journal of Human Genetics 86, 581–591, April 9, 2than 400 liver samples from people of European descent.11
This genetics of gene expression study resulted in the
detection of 3309 unique eSNPs at a false discovery rate
(FDR) % 10%.11 The second multitissue GGE cohort
comprised patients of European descent who underwent
Roux-en-Y gastric bypass surgery. Liver, subcutaneous
adipose, and omental adipose tissues were collected from
each patient at the time of surgery at Massachusetts
General Hospital. Genomic DNA was extracted from liver
tissues, and total RNA was extracted from liver, subcuta-
neous adipose, and omental adipose tissues. Each RNA
sample was proﬁled on a custom 44K Agilent array, and
each DNA sample was genotyped on an Illumina 650Y
BeadChip array. Successful gene expression proﬁling
results were collected from 707 liver samples, 916 omental
adipose samples, and 870 subcutaneous adipose samples.
The method for identifying eSNPs was detailed by
Schadt et al.11 In brief, the gene expression data were ﬁrst
adjusted by age, race, gender, and surgery year in a linear
model, and then the expression-SNP correlation was
analyzed with the use of the adjusted expression data. All
expression traits were tested for association with each of
the genotyped SNPs meeting the quality control (QC)
criteria. The association p values were adjusted to control
for testing of multiple SNPs and expression traits with
the use of an empirically determined FDR constrained
to be% 10%.11 These two GGE cohorts allowed us to iden-
tify a total of 20,563 distinct eSNPs to 9964 known
genes (8693, 11,742, and 11,392 eSNPs identiﬁed from
liver, omental adipose, and subcutaneous adipose tissues,
respectively). In comparing eSNPs identiﬁed in indepen-
dent tissues from the same cohort, there was considerable
overlap between any given pairing of tissues: 72.0% of
the eSNPs identiﬁed in liver, 79.0% of those found in
omental adipose, and 80.5% from subcutaneous adipose
were also found in the other two tissues. Thus, each
tissue provides approximately ~30% tissue-speciﬁc eSNPs
detectable in the studied samples (H.Z., unpublished
data; under revision at PLoS Genetics, manuscript available
upon request).
To generate T2D association p values for the eSNPs
derived from the GGE studies, we used individual-level
genotype data on 393,143 autosomal SNPs in 1924 cases
and 1500 population-based controls (UK Blood Services
controls) generated from theWTCCCT2D study.28 Because
different SNP panels were used in the different GGE studies
and GWAS, many of the eSNPs were not genotyped in
WTCCC. Therefore, using the WTCCC data, we imputed
genotypes for autosomal eSNPs that were present in
HapMap Phase II but were not present in the Affymetrix
500K chip used by WTCCC or did not pass direct genotyp-
ing QC (QC standards detailed in the WTCCC publica-
tion28). Genotypes were imputed with the use of the
genotype data fromWTCCC and phased HapMap II geno-
type data from the 60 CEU HapMap founders. Imputation
was performed with the software package MACH 1.0.29
We retained SNPs that had an estimated minor allele010
frequency > 0.01 in the control sample. Only those with
high imputation conﬁdence (R2 > 0.4) were included in
the analysis.7 Imputed SNPs were then tested for T2D
association. Summary association statistics from the
DIAGRAM Consortium, which combines the results from
theWTCCC,28 the Diabetes Genetics Initiative (DGI),4 and
Finland–United States Investigation of NIDDM Genetics
(FUSION),5 were used for validation.
In addition to using DIAGRAM as a validation cohort, we
used a weighted subtraction algorithm to derive T2D asso-
ciation p values from the samples in DIAGRAM, excluding
the WTCCC samples. The DIAGRAM association statistics
were derived from a ﬁxed-effect weighted average of the
summary Z scores from the three cohorts,7,30 which
comprised 10,128 samples in total (4862WTCCC samples,
2931 DGI samples, and 2335 FUSION samples). The
cohort-speciﬁc weight was proportional to the square
root of the effective number of individuals in the cohort;
the squared weights were chosen to sum to 1.7 Therefore,
the Z score of non-WTCCC samples can be approximated
by ZNonWTCCC ¼ ZDIAGRAM WWTCCCZWTCCC=WNonWTCCC,
in which ZDIAGRAM and ZWTCCC are the Z scores converted
from the two-sided p values from DIAGRAM and WTCCC,
respectively. We then converted ZNon-WTCCC to a two-sided
p value, PNon-WTCCC, which represented the association
signiﬁcance from the non-WTCCC samples.30 ZDIAGRAM
and ZWTCCC were assumed to have the same sign; thus,
the same allelic effect direction was assumed in the
WTCCC and DIAGRAM results. Note that although the
WTCCC cohort contains 1924 cases and 2938 controls,
the effective WTCCC sample size is expected to be less
than 4862 because of the imbalance in sample size
between cases and controls. Further, we imputed the unas-
sayed SNP genotypes on the basis of individual-level
WTCCC genotype data of 1924 cases and 1500 controls.
Therefore, the effective sample size and the weight of
WTCCC data were approximated by 1924 þ 1500 ¼ 3424
and WWTCCC ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
3424=10128
p ¼ 0:58, respectively. The
effective sample sizes of DGI and FUSION studies were
approximated by the actual sample sizes, because the cases
and controls are quite balanced in each study. The weight
of non-WTCCC samples was calculated as WNonWTCCC ¼ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2931þ 2335=10128p ¼ 0:72.
To minimize multiple-testing concerns, we chose to use
KEGG pathways because these represent relatively well-
deﬁned known biological pathways, rather than the more
broad functional categories deﬁned in other databases
such as Gene Ontology (GO).31 Although our method can
be applied to GO-derived gene sets, GO has a hierarchical
structure that results in thousands of pathways for testing
andhence increasesmultiple testing if all depths are consid-
ered. If analyses were restricted to a particular GO level, the
presence of highly varied depths among GO terms may
affect the reliability of statistical signiﬁcance tests.32 There-
fore, use of gene sets derived from GO must proceed with
caution.Out of all of the KEGGhumanpathways, we tested
110 pathways that contained between 20 and 200 genesThe Amassociated with eSNPs. The cutoff of 20–200 genes was
selected as the optimal range for gene sets on the basis of
the power of the algorithm17 and of avoiding the artiﬁcial
signiﬁcance of large gene sets introduced by larger number
of comparisons.18 We note that pathways containing
between 10 and 300 genes associated with eSNPs produced
similar results (data not shown). To better characterize the
sensitivity and speciﬁcity of our approach, we designed
two artiﬁcial positive control pathways17 and ten artiﬁcial
negative control pathways. The ﬁrst positive-control
pathway contained 18 genes that were most adjacent to
the 18 replicated SNPs from theWTCCCGWAS;33 the other
positive control pathway contained the same genes but
was diluted by the addition of 40 genes that were randomly
selected from the set of genes associated with at least one
eSNP (per gene) across the human genome. The negative
control pathways were composed of genes randomly
selected from the set of genes associated with at least
one eSNP across human genome, but excluding the 18
genes identiﬁed in the WTCCC GWAS. The gene counts
of the negative control pathways ranged from 20 to 200
in increments of 10 (20, 40,., 200). These artiﬁcial control
pathways were analyzed together with the 110 KEGG
pathways.
We modiﬁed the algorithm proposed by Wang et. al16 to
integrate the eSNP information into the pathway-based
GWAS analysis. Each SNP was tested for T2D association,
producing a p value (referred to here as PT2D). In our inte-
grative genomics algorithm, we represented a gene by the
eSNPs signiﬁcantly associated with that gene’s abundance
of transcript(s) in liver or adipose tissue in any of the GGE
studies considered. When one eSNP was located within
the shared regions of two overlapping or neighboring
genes and associated with both gene expression levels,
we mapped the eSNP to both genes. We assigned the
PT2D of the eSNP mapped to the gene as the PT2D of the
gene. When multiple eSNPs were identiﬁed as associated
with the same gene, the eSNP with the most signiﬁcant
PT2D was taken as the eSNP for the gene, and that eSNP
was designated as the representative eSNP. From our obser-
vations, when there were multiple detected cis-eSNPs for
a given gene, they were usually located in a single LD
block. That is, the multiple eSNPs for a given gene were
usually detected because of their correlations to each
other and/or their correlations with the true causal eSNP.
Therefore, using all of these eSNPs would not add more
independent information. The signiﬁcance of each gene
set (denoted by Enrichment Score, ES*(s), s ¼ 1.S, in
which S is the number of tested gene sets) was judged
with the use of a Kolmogorov-Smirnov one sided test
statistic on the basis of the deviation from a uniform
distribution of equal size. Ten thousand permutations
were performed, in which the T2D case-control label was
randomized, for evaluation of the signiﬁcance level of
the gene set. In each permutation (denoted by d ¼ 1.D,
in which D ¼ 10,000, total number of permutations), we
repeated the above three steps—i.e., (1) test for SNP-T2Derican Journal of Human Genetics 86, 581–591, April 9, 2010 583
Table 1. Pathways with Significant Enrichment in the WTCCC data and Significant or Suggestive Enrichment in the DIAGRAM or non-WTCCC Replication Data
Pathway Enrichment p Value eSNP PT2D
Pathwaya Gene Count
Genes with
eSNP FDRb WTCCCc Diagramd Non-WTCCCe
Genes with
p < 0.01f eSNP WTCCC Diagram Non-WTCCCe
Tight junction 186 39% 0.06 1.20 3 103 5.40 3 103 9.61 3 102 MYH1 rs1989811 4.40 3 105 1.60 3 104 5.23 3 102
MYH2 rs2097657 4.40 3 105 4.30 3 104 1.12 3 101
EXOC4 rs6976491 2.10 3 104 6.70 3 104 8.39 3 102
CLDN23 rs2976929 4.30 3 104 6.90 3 103 3.64 3 101
CSNK2B rs1077394 5.50 3 104 2.10 3 105 1.85 3 103
Adherens junction 110 45% 0.18 7.40 3 103 2.40 3 102 8.08 3 102 CSNK2B rs1077394 5.50 3 104 2.10 3 105 1.85 3 103
Calcium signaling
pathway
239 39% 0.19 9.60 3 103 1.60 3 102 3.20 3 101 PDE1A rs6711862 2.30 3 102 1.70 3 103 1.18 3 102
GRIN2C rs6501741 3.00 3 102 7.10 3 103 4.73 3 102
ITPR1 rs4684443 1.70 3 102 8.00 3 103 7.95 3 102
AGTR1 rs16861027 3.30 3 102 8.30 3 103 5.22 3 102
Hematopoietic cell
lineage
120 33% 0.19 1.70 3 102 3.60 3 102 3.66 3 101 CR1 rs1323720 6.30 3 103 6.30 3 103 1.13 3 101
HLA-DQA1/
HLA-DRB1/
HSPA1B
rs1077394 5.50 3 104 2.10 3 105 1.85 3 103
HLA-G rs2256902 8.10 3 104 1.10 3 103 6.80 3 102
Complement and
coagulation cascades
108 46% 0.19 1.80 3 102 5.30 3 102 1.65 3 102 CR1 rs1323720 6.30 3 103 6.30 3 103 1.13 3 101
C4A/B rs1077394 5.50 3 104 2.10 3 105 1.85 3 103
C5 rs10818503 4.50 3 103 8.80 3 103 1.79 3 101
PPAR signaling pathway 92 43% 0.2 2.90 3 102 2.70 3 102 6.46 3 101 PPARD rs9368849 7.60 3 104 1.70 3 103 1.02 3 101
SCD rs11190462 9.20 3 102 6.10 3 103 1.45 3 102
Ether lipid metabolism 45 51% 0.2 3.10 3 102 2.40 3 101 8.03 3 102 AGPAT6 rs919035 1.40 3 101 3.20 3 103 3.75 3 103
TGF-b signaling pathway 134 45% 0.2 3.50 3 102 2.10 3 102 5.44 3 102 RBL2 rs4784312 2.30 3 104 8.80 3 104 1.00 3 101
INHBB rs11677557 5.60 3 101 3.50 3 103 3.44 3 104
SMURF2 rs17401012 1.50 3 101 9.20 3 103 1.42 3 102
Antigen processing and
presentation
119 41% 0.46 3.90 3 102 3.34 3 104 2.12 3 103 HLA-DQA1/
HLA-DRB1/ HSPA1B
rs1077394 5.50 3 104 2.10 3 105 1.85 3 103
HLA-B/ HSPA1L rs2260000 1.80 3 103 7.20 3 104 2.98 3 102
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The Amassociation and record PdT2D for each SNP; (2) take the most
signiﬁcant PdT2D among all of the eSNPs corresponding to
a given gene as the PdT2D of the gene; (3) calculate the
ES(s,d) for the gene set. The permutation approach gives
an empirical distribution for the ES score for a set of
genes under no association while keeping their LD
structure unchanged.16 A nominal signiﬁcance level for
ES*(s) was computed as the fraction of all permutations
whose ES(s) is higher than ES*(s). To compare gene sets
of different size and adjust for multiple-hypothesis testing,
a normalized enrichment score (NES) was then produced:
NES  ðsÞ ¼ ES  mean½ESðs,dÞ=SD½ESðs,dÞ.16 The FDRs
corresponding to an NES*(s) were computed as the ratio
between the fraction of the NESs of all gene sets in all
permutations higher than NES*(s) and the fraction of the
NES*s of all gene sets higher than NES*(s) in the observed
data.16 The GSEA algorithm used a weighted Kolmo-
gorov-Smirnov statistic to calculate the excess of associa-
tion signals in each pathway.15,16 In our modiﬁed algo-
rithm, we computed a test statistic for a gene only if the
gene corresponded to an eSNP. Thus, there is no rank
statistic for a gene with the reference being all of the genes
represented by SNPs in the GWAS. Therefore, we adopted
a regular Kolmogorov-Smirnov one-sided statistic to quan-
tify the excess of association signals compared to a random
uniform distribution.
Twenty-three out of the 110 KEGG pathways (21%)
reached a nominal p value % 0.05 on the basis of the
WTCCC GWAS results, four times higher than the number
expected by chance (0.05 3 110 ¼ 5.5), suggesting that
T2D genes possibly fall in multiple pathways. Sixteen of
these 23 pathways reached an FDR of less than 20%
(Table 1; full signiﬁcance results of 110 KEGG pathways
in Table S1, available online). These include known
candidate T2D pathways such as PPAR signaling, calcium
signaling, TGF-b signaling, cell communication, and pan-
creatic cancer pathway. It is of note that some of the iden-
tiﬁed signiﬁcant KEGG pathways have many overlapping
genes. For example, 86% of the genes in the N-Glycan
biosynthesis pathway are also in the pathway Glycan
structures–biosynthesis 1, with genes encoding manosi-
dases and mannosyltransferases, being the common
driving genes for the observed enrichment for both path-
ways, and genes encoding carbohydrate sulfotransferases
being the additional driving genes for the overrepre-
sentation of the Glycan structures–biosynthesis pathway.
Approximately 60% of the genes in the bladder cancer
pathway are also in the pancreatic cancer pathway, with
oncogenes CCND1 (MIM *168461) and KRAS (MIM
*190070) as well as those encoding vascular endothelial
growth factors VEGFA (MIM þ192240) and VEGFB (MIM
*601398) being the key common genes that drive the
enrichment of both pathways, and the signal transduction
genes SMAD3 (MIM *603109) andMAPK10 (MIM *602897)
being additional genes that drive the signiﬁcance of the
pancreatic cancer pathway. Therefore, the correlation
among KEGG pathways contributes to the observed excesserican Journal of Human Genetics 86, 581–591, April 9, 2010 585
number of enriched pathways, with core genes driving the
enrichment of multiple pathways.
Both artiﬁcial positive control pathways were ranked as
the top pathways identiﬁed by our procedure. Among the
18 T2D genes derived from the replicated GWAS SNPs, six
genes, namely NOTCH2 (MIM *600275), ADAMTS9 (MIM
*605421), JAZ1, TSPAN8 (MIM *600769), PPARG (MIM
*601487), and CDKAL1 (MIM *611259) had at least one
eSNP (eSNPs detailed Table S2). On the basis of the
HapMap data, four out of the six eSNPs that we used to
represent these six GWAS genes were in reasonable LD
with the correspondingGWAS hits and thus are representa-
tive of the known T2D SNPs. However, the eSNP for PPARG
was not in LD with the GWAS SNP, and the eSNP for
CDKAL1 is over 600 kb away from the GWAS SNP. These
two eSNPs may themselves be functional or in LD with
other functional SNPs (the LD structures between eSNPs
and GWAS SNPs are detailed in Table S3). The positive
control pathway corresponding to these six genes had
a nominal p < 0.0001 (FDR < 0.0001). The other 46-gene
positive control pathway had a p ¼ 0.0006 (FDR ¼ 0.005).
Although the 18 GWAS genes were only neighboring
genes of replicated GWAS SNPs and may not necessarily
represent functionally validated T2D causal genes, some
of these 18 genes, especially the six genes with eSNPs that
show strong T2D association, may be more likely to repre-
sent true T2D causal genes. Thus, it is encouraging to
observe the highly signiﬁcant enrichment of these path-
ways as a positive control of our approach.
The 20-gene negative control pathway had a p ¼ 0.45,
whereas the 200-gene negative control pathway had
a p ¼ 0.33, neither of which corresponded to an FDR < 1
(Table S1). The p values for the other ten negative control
pathways tended to get smaller as the gene sets became
larger, conﬁrming the previously noted bias of large gene
sets in this type of pathway-based approach.18 However,
an alternative explanation for this trend could be that
the eSNPs derived from liver and adipose represent a func-
tional set of SNPs that themselves are enriched for associ-
ating with T2D. The fact that these SNPs are signiﬁcantly
correlated with gene expression in T2D-related tissues
provides for the possibility that they may tend to be
slightly enriched for association to T2D in comparison to
randomly selected SNPs across the human genome, where
the inverse relationship between enrichment p value and
set size could reﬂect the increasing power expected with
increasing set sizes. We believe that this strengthens the
power of our approach to detect stronger signals for true
disease-correlated pathways, although it may also slightly
contribute to the excess number of enriched pathways
that we observed.
We next sought to replicate these ﬁndings by investi-
gating the PT2D for the eSNPs corresponding to the genes
for the 23 KEGG pathways identiﬁed from the WTCCC
T2D GWAS with a p value% 0.05 by using summary-level
data from the DIAGRAM Consortium and the derived
signiﬁcance of the association in the DIAGRAM samples,586 The American Journal of Human Genetics 86, 581–591, April 9, 2excluding the WTCCC samples (PNon-WTCCC). We tested
whether PDIAGRAM-T2D and PNon-WTCCC for the eSNPs corre-
sponding to genes in a given pathway were signiﬁcantly
different from a uniform distribution based on a Komo-
gorov one-sided statistic, respectively. From the DIAGRAM
samples, nine pathways,—tight junction, adherens junc-
tion, neuroactive ligand-receptor interaction, calcium sig-
naling, hematopoietic cell lineage, N-Glycan biosynthesis
(Glycan structures–biosynthesis 1), PPAR signaling, TGF-b
signaling, and antigen processing and presentation path-
way—showed deviations from the null distribution
(p value% 0.05 in Table 1 and Figure 1). The complement
and coagulation cascades pathway showed a marginal
signiﬁcance level (p ¼ 0.053). From the non-WTCCC
samples, complement and coagulation cascades pathway,
TGF-b signaling pathway, and antigen processing and
presentation pathway showed deviations from the null dis-
tribution. Adherens junction, ether lipid metabolism path-
way, and tight junction demonstrated a consistent trend
in the same direction as that observed in the WTCCC,
but at suggestive signiﬁcance levels (p ¼ 0.080, p ¼
0.081, and p ¼ 0.096, respectively; Table 1 and Figure 1).
The signiﬁcance patterns were fairly consistent between
the non-WTCCC and the WTCCC studies for the repli-
cated pathways. Only genes and their representative eSNPs
with DIAGRAM PT2D % 0.01 for each consistent pathway
are listed in Table 1, although we note that there are
many more eSNPs associated with each pathway. Notably,
each of the individual eSNPs showed only subtle T2D asso-
ciations, supporting the hypothesis that many genes with
small effect sizes together contribute to T2D.4,7,16 Details
of the pathway genes, their corresponding eSNPs, expres-
sion tissues, eSNP-expression-correlation p values, eSNP
WTCCC PT2D, and eSNP DIAGRAM PT2D are shown in
Table S2.
A majority of the pathways identiﬁed from this study,
such as calciumsignaling, PPAR signaling,N-glycanbiosyn-
thesis, TGF-b signaling, andcell communication, havebeen
implicated as important T2D pathways in the literature.
For example, calcium signaling is crucial for insulin secre-
tion in pancreatic b-cells34,35 as well as insulin-mediated
glucose uptake in skeletal muscle.36–38 PPAR signaling
plays a critical role in glucose homeostasis and insulin
sensitivity, and PPAR-gamma agonists such as thiazolidine-
diones have been used to treat T2D.39–42 N-glycan deﬁ-
ciency in glycoproteins has been linked to islet damage
and T2D.43–45 TGF-b signaling has been implicated to be
important for pancreatic islet development.46,47 Islet-to-
islet or b-to-b cell communicationhas shown to be the basis
for insulin secretion.48,49 The hematopoietic cell lineage
pathway reﬂects mainly the immune response and the
inﬂammatory pathway, which have been extensively
linked to diabetes and obesity.50,51
Not only does our approach support the above men-
tioned pathways with signiﬁcant enrichment scores, it
provides support for less characterized candidate path-
ways for roles in T2D, including tight junction, adherent010
Figure 1. Quantile Quantile Plots of the Representative eSNP p values for the Eight Pathways
The eight pathways are: (A) adherens junction, (B) antigen processing and presentation, (C) complement and coagulation cascades, (D)
ether lipid metabolilsm, (E) hematopoietic cell lineage, (F) TGF-b signaling pathway, (G) tight junction, and (H) PPAR signaling pathway.
On each plot, the x axis is –log10 of the expected p values of an equally sized set of SNPs under a uniform distribution. The y axis is –log10
of the observed p values. The SNPs presented in each plot are the representative eSNPs for genes in the corresponding pathway. The
representative eSNPs are identiﬁed on the basis ofWTCCC PT2D. Red dots represent their p values (PT2D) based onWTCCC. Blue triangles
represent their p values (PT2D) based on DIAGRAM meta-analysis. Green diamonds represent their p values (PT2D) based on DIAGRAM
samples excluding the WTCCC detection samples. Black solid lines denote the uniform null distribution. Dashed lines denote 95%
conﬁdence intervals of deviation from the null distribution.junction, complement and coagulation, and antigen pro-
cessing and presentation. Their enrichment patterns were
replicated with the use of the DIAGRAM meta-analysis
data (Figure 1). As the most signiﬁcant pathway from
our analysis, tight junction has been implicated mainly in
complications of diabetes, such as nephropathy and reti-
nopathy, because of its function inmodulating intercellular
permeability.52–55 However, there is evidence supporting
a role for tight junction molecules in the regeneration of
pancreatic islets and the pathogenesis of T1D.56,57 The ad-
herens junction pathway may affect T2D in a similar
fashion. The complement and coagulation pathway may
mediate T2D indirectly through its effect on obesity.58–60
The antigen processing and presentation pathway has
been associated with T1D in large-scale GWAS;28,61 its rela-
tionship with T2D has also been implicated.62
Mootha et al. have previously shown that oxidative
phosphorylation is associated with diabetes through the
use of gene expression proﬁling.61 In our analysis using
GWAS data, the oxidative phosphorylation pathway has
an enrichment p value of 0.087. Therefore, we were not
able to replicate the oxidative phosphorylation pathway.
One possible explanation is, as Perry et al. discussed, that
the changes in oxidative phosphorylation gene expression
may be a result of the T2D status, rather than the cause ofThe AmT2D, as others have suggested.17 It is of particular note
that our method focuses on causal pathways, given that
genetic variations represent causal anchors that enable
causal inference, whereas gene-expression-based analysis
cannot typically differentiate causal from reactive path-
ways. Among the previous pathway-based GWAS, six
KEGG pathways with a nominal p % 0.05 had been
identiﬁed.17 Of these six pathways, we conﬁrmed the
TGF-b signaling pathway (p ¼ 0.035) and the olfactory
transduction pathway (p ¼ 0.049). However, the WNT
signaling pathway, which has been strongly linked to
T2D58–60 and which ranked as a top pathway in previous
analyses,17 as well as the three other pathways, including
galactose metabolism, pyruvate metabolism, and T2Dmel-
litus, were not among the top hits in our study. Among
these four pathways that were not replicated, galactose
metabolism (13 genes with eSNPs) and T2D (15 genes
with eSNPs) pathways were not represented in our analysis
because the number of genes with eSNPs in these pathways
did not reach our 20–200 selection criteria (p ¼ 0.263 and
0.102, respectively, in the set size threshold relaxed test);
the WNT signaling pathway and the pyruvate metabolism
pathway had enrichment p values of 0.076 and 0.373,
respectively. One possible explanation for the discrepancy
could be the limited coverage of representative SNPs forerican Journal of Human Genetics 86, 581–591, April 9, 2010 587
each pathway. For instance, certain GWAS SNPs in these
pathways may not affect gene expression, but may instead
alter posttranscriptional mechanisms such as mRNA
splicing or protein function. In other words, eSNP selec-
tion based on the GGEmight havemissed classes of impor-
tant functional GWAS SNPs and thus caused a loss of
power. Additionally, our GGE cohorts might not be pow-
ered enough to pick up all relevant eSNPs. First, the eSNPs
used in this study were from liver and adipose tissues.
Although these are relevant tissues for T2D, other key
tissues such as islet, muscle, and brain were not available
for eSNP discovery, and hence ~30% of the tissue-speciﬁc
eSNPs were likely missing from our analysis. Second,
studying gene expression in non-T2D individuals may
have caused some relevant eSNPs to go undetected. Our
ﬁrst GGE cohort was a population-based random sample,
whereas the second was an obese cohort; hence, neither
represented individuals that were speciﬁcally sampled
on the basis of T2D status. Third, the sample sizes of
the GGE cohorts are limited and so lack power to detect
more modestly sized effects. Indeed, when comparing
the eSNP ﬁndings from the two cohorts, 20.6% liver eSNPs
identiﬁed from the ﬁrst cohort were identiﬁed as liver
eSNPs in the second cohort, supporting our speculation
of limited eSNP coverage from cohorts of different sample
sizes and sample characteristics. In our analysis, we pooled
the eSNPs from the two cohorts in the three tissues as a
starting point, mainly to improve power to detect path-
way-based associations. To further address the caveats
associated with limited coverage of representative pathway
SNPs, a more comprehensive functional annotation of
SNPs in additional key physiological tissues from larger
populations are needed, and disease-speciﬁc samples that
incorporate alternative splicing, noncoding RNA, proteo-
mics, metabolomics, and possibly other biological pro-
cesses, such as epigenetics, will be needed.
Because DIAGRAM has only summary-level statistics
available, we did not use the permutation-based signiﬁ-
cance test. Instead, we used a Komogorov test to compare
the representative eSNP PT2D to the uniform distribution.
Because it is not common to have two representative eSNPs
in one LD block, the bias caused by underlying LD is not
expected to be severe. In the subtraction algorithm, we
assumed that the same allelic effect direction was reported
in the DIAGRAM and WTCCC results. This assumption
holds for most SNPs, but will cause bias in Pnon-WTCCC
estimates for the SNPs in which the opposite allelic effects
were detected in the two studies. The validation p values
of the pathways fromnon-WTCCC samples aremoderately
signiﬁcant or only suggestive; therefore, future studies will
be needed to fully explore these ﬁndings.
In conclusion, our results demonstrate the potential
applicability of integrating the GGE studies and pathway-
based approaches to the interpretation and further mining
of GWAS data. The concept is that intuitive and straightfor-
ward: SNPs that are associated with gene expression in
disease-relevant tissues are more likely to be functionally588 The American Journal of Human Genetics 86, 581–591, April 9, 2relevant SNPs; thus, leveraging this information can poten-
tially provide signiﬁcant power to identify disease path-
ways. In the span of just a few short years in which large-
scale GWAS have been carried out, the realization that
tractable drug targets and clinically useful biomarkers of
disease are not immediately falling out of the data has for
some reduced the enthusiasm for the GWAS approach,
intensifying the debate over whether GWAS are the best
strategy to elucidate the causes of disease.63–65 This integra-
tion of eSNPs and well-deﬁned biological pathways
provides a novel approach for identifying disease suscepti-
bility paths rather than the single SNPs or genes tradition-
ally identiﬁed through GWAS and thus can potentially
extract value from thewealth of data currently being gener-
ated by GWAS. Although the GO and other pathway
databases will no doubt be of use in searching for enrich-
ments similar to that which was done for the KEGG path-
ways, the primary aim is to present this new approach to
leveraging eSNP data as a ﬁlter to enhance power to detect
the enrichments. Diabetes pathogenesis involves many
pathways operating in different tissues and distinct physio-
logical processes, such as blunted insulin signaling and
failure of beta cells to compensate by producing more
insulin. Our approach borrows the strength of GGE, which
provides putative functional bridges between GWAS SNPs
and candidate genes or pathways; it thus represents an
advance in helping to identify biological mechanisms
underlying GWAS ﬁndings.
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